Clinical Trial: Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
Brief Summary: The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines in healthy volunteers. The concentration dopamine and serotonin in thrombocytes with and without medication will also be evaluated.
Detailed Summary:
- To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours.
- To compare these concentrations with the concentrations catecholamines in thrombocytes of healthy controls.
- To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and patients with low grade neuroendocrine tumours with and without medication.
Sponsor: University Medical Center Groningen
Current Primary Outcome: Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls. [ Time Frame: one year ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication. [ Time Frame: one year ]
Original Secondary Outcome: Same as current
Information By: University Medical Center Groningen
Dates:
Date Received: July 19, 2011
Date Started: July 2011
Date Completion:
Last Updated: May 7, 2012
Last Verified: May 2012
